Switch theme
Sign up to access all valuation multiples
Enfusion Inc is a software-as-a-service (SaaS) provider focused on transforming the investment management industry. The products and services that comprise its solution are designed to eliminate technology and information barriers, empowering investment managers to confidently make and execute better-informed investment decisions in real time. It simplifies investment and operational workflows by unifying mission-critical systems and coalescing data into a single dataset resulting in a single source of truth. It generates maximum revenue from the Americas, followed by Asia Pacific and Europe, the Middle East, and Africa.
2021
1.1K+
LTM Revenue $212M
LTM EBITDA $46.0M
$991M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Enfusion has a last 12-month revenue of $212M and a last 12-month EBITDA of $46.0M.
In the most recent fiscal year, Enfusion achieved revenue of $202M and an EBITDA of $17.9M.
Enfusion expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Enfusion valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $175M | $202M | XXX | XXX | XXX |
| Gross Profit | $103M | $117M | XXX | XXX | XXX |
| Gross Margin | 59% | 58% | XXX | XXX | XXX |
| EBITDA | $21.9M | $17.9M | XXX | XXX | XXX |
| EBITDA Margin | 13% | 9% | XXX | XXX | XXX |
| Net Profit | -$7.7M | $6.0M | XXX | XXX | XXX |
| Net Margin | -4% | 3% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Enfusion's stock price is $11.
Enfusion has current market cap of $1.0B, and EV of $991M.
See Enfusion trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $991M | $1.0B | XXX | XXX | XXX | XXX | $0.22 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Enfusion has market cap of $1.0B and EV of $991M.
Enfusion's trades at 4.7x LTM EV/Revenue multiple, and 21.5x LTM EBITDA.
Analysts estimate Enfusion's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Enfusion and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $991M | XXX | XXX | XXX |
| EV/Revenue | 4.9x | XXX | XXX | XXX |
| EV/EBITDA | 55.3x | XXX | XXX | XXX |
| P/E | 363.0x | XXX | XXX | XXX |
| P/E/Growth | 1.1x | XXX | XXX | XXX |
| EV/FCF | 41.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpEnfusion's NTM/LTM revenue growth is 17%
Enfusion's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Enfusion's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Enfusion's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Enfusion and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 9% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -18% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 26% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 12% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 39% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 13% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 65% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Allfunds Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Bravura Solutions | XXX | XXX | XXX | XXX | XXX | XXX |
| Change Financial | XXX | XXX | XXX | XXX | XXX | XXX |
| Computershare | XXX | XXX | XXX | XXX | XXX | XXX |
| FINEOS | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Enfusion acquired XXX companies to date.
Last acquisition by Enfusion was XXXXXXXX, XXXXX XXXXX XXXXXX . Enfusion acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Enfusion founded? | Enfusion was founded in 2021. |
| Where is Enfusion headquartered? | Enfusion is headquartered in United States of America. |
| How many employees does Enfusion have? | As of today, Enfusion has 1.1K+ employees. |
| Who is the CEO of Enfusion? | Enfusion's CEO is Mr. Oleg Movchan. |
| Is Enfusion publicy listed? | Yes, Enfusion is a public company listed on NYS. |
| What is the stock symbol of Enfusion? | Enfusion trades under ENFN ticker. |
| When did Enfusion go public? | Enfusion went public in 2021. |
| Who are competitors of Enfusion? | Similar companies to Enfusion include e.g. Allfunds Group, Bravura Solutions, Change Financial, Computershare. |
| What is the current market cap of Enfusion? | Enfusion's current market cap is $1.0B |
| What is the current revenue of Enfusion? | Enfusion's last 12-month revenue is $212M. |
| What is the current EBITDA of Enfusion? | Enfusion's last 12-month EBITDA is $46.0M. |
| What is the current EV/Revenue multiple of Enfusion? | Current revenue multiple of Enfusion is 4.7x. |
| What is the current EV/EBITDA multiple of Enfusion? | Current EBITDA multiple of Enfusion is 21.5x. |
| What is the current revenue growth of Enfusion? | Enfusion revenue growth between 2023 and 2024 was 16%. |
| Is Enfusion profitable? | Yes, Enfusion is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
